Wang LL, Wang Q, Hong Y, Ojo O, Jiang Q, Hou YY, et al
1B and S1)
This supports a model in which GLP-1RAs may exert direct plaque-modifying effects, although definitive human plaque-level confirmation remains limited
Yes, switching is clinically possible, but it must be entirely managed by a qualified healthcare professional to ensure your dose is converted safely without causing severe digestive side effects.
Long-term safety data, including pancreatitis risk, gallbladder events, and any potential thyroid C-cell findings, will continue to accumulate through the Phase 3 TRIUMPH program
For many patients, cost has historically been one of the biggest barriers to treatment, with retail cash prices for brand-name Wegovy and Zepbound previously exceeding $1,000 per month